C. Sasse

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

Scott E. Smith, K. Papadopoulos, A. Thyss, 2016, Leukemia & lymphoma.

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

J. Perfect, G. Rahav, F. Marty, 2016, The Lancet. Infectious diseases.

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

M. Milowsky, S. Srinivas, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

M. Milowsky, S. Srinivas, A. Balar, 2021 .

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

M. Milowsky, S. Srinivas, J. Rosenberg, 2020 .

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

M. Milowsky, S. Srinivas, J. Rosenberg, 2020 .

Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).

S. Srinivas, J. Rosenberg, P. O’Donnell, 2022, Journal of Clinical Oncology.

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

A. Benson, J. Bridgewater, C. Van Sant, 2016, Clinical Cancer Research.